CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

In oncology, immunotherapy stands as a transformative approach for treating solid tumors, notably through pioneering treatments like immune checkpoint ...

Chimeric antigen receptor (CAR) T-cell therapy has had a transformational impact on the treatment of aggressive hematologic malignancies. The therapies have given life-extending options to ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

However, CAR-T cell application in solid tumors remains challenging. There is an unmet clinical need for better cellular therapies for solid tumors. The team of researchers, led by Xiaowei ...

CAR-T therapies have transformed the treatment of various blood cancers, but have been less effective for solid tumours, in part because they find it difficult to target cancer cells, as well as ...

Abstract Title: Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies ...

Get Instant Summarized Text (Gist) A three-drug cocktail has been identified to enhance CAR-T cell therapy by preserving T-memory stem cells (T SCM), crucial for long-term persistence.The cocktail ...